Nicotinamide and phosphate homeostasis in chronic kidney disease

Current Opinion in Nephrology and Hypertension

Volumn 25, Issue 4, 2016, Pages 285-291

  Ginsberg, Charles ^a   Ix, Joachim H ^a,b,c  

^a UNIVERSITY OF CALIFORNIA SAN DIEGO   (United States)

^b VA SAN DIEGO HEALTHCARE SYSTEM   (United States)

^c UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

kidney disease; mineral bone disorder; nicotinamide; osteodystrophy

Indexed keywords

NICOTINAMIDE; NICOTINIC ACID; PHOSPHATE; VITAMIN B COMPLEX;

CHRONIC KIDNEY DISEASE; DRUG ABSORPTION; DRUG EFFICACY; DRUG MECHANISM; DRUG METABOLISM; DRUG SAFETY; END STAGE RENAL DISEASE; FOLLOW UP; HUMAN; HYPERGLYCEMIA; HYPERPHOSPHATEMIA; HYPERTRANSAMINASEMIA; HYPERURICEMIA; LEUKOPENIA; LIVER TOXICITY; NONHUMAN; PHOSPHATE BLOOD LEVEL; PHOSPHATE EXCRETION; PHOSPHATE METABOLISM; PHOSPHATE TRANSPORT; PHOSPHATE URINE LEVEL; PRIORITY JOURNAL; PROTEIN EXPRESSION; RANDOMIZED CONTROLLED TRIAL (TOPIC); REVIEW; THROMBOCYTOPENIA; URINARY EXCRETION; ANIMAL; BLOOD; CHRONIC KIDNEY DISEASE-MINERAL AND BONE DISORDER; CHRONIC KIDNEY FAILURE; COMPLICATION; HOMEOSTASIS; METABOLISM;

ANIMALS; CHRONIC KIDNEY DISEASE-MINERAL AND BONE DISORDER; HOMEOSTASIS; HUMANS; HYPERPHOSPHATEMIA; NIACINAMIDE; PHOSPHATES; RENAL INSUFFICIENCY, CHRONIC; VITAMIN B COMPLEX;

EID: 84969939908     PISSN: 10624821     EISSN: 14736543     Source Type: Journal    
DOI: 10.1097/MNH.0000000000000236     Document Type: Review

References (45)

1. Lemoine S, Fournier T, Kocevar G, et al. Intracellular phosphate dynamics in muscle measured by magnetic resonance spectroscopy during hemodialysis. J Am Soc Nephrol 2015; doi: 10. 1681/ASN. 2015050546. [Epub ahead of print]
2. O'Seaghdha CM, Hwang SJ, Muntner P, et al. Serum phosphorus predicts incident chronic kidney disease and end-stage renal disease. Nephrol Dial Transplant 2011; 26:2885-2890.
3. Kestenbaum B, Sampson JN, Rudser KD, et al. Serum phosphate levels and mortality risk among people with chronic kidney disease. J Am Soc Nephrol 2005; 16:520-528.
4. Foley RN, Collins AJ, Herzog CA, et al. Serum phosphorus levels associate with coronary atherosclerosis in young adults. J Am Soc Nephrol 2009; 20:397-404.
5. Ix JH, De Boer IH, Peralta CA, et al. Serum phosphorus concentrations and arterial stiffness among individuals with normal kidney function to moderate kidney disease in MESA. Clin J Am Soc Nephrol 2009; 4:609-615.
6. Levin A, Bakris GL, Molitch M, et al. Prevalence of abnormal serum vitamin D, PTH, calcium, and phosphorus in patients with chronic kidney disease: results of the study to evaluate early kidney disease. Kidney Int 2007; 71:31-38.
7. Fang Y, Ginsberg C, Sugatani T, et al. Early chronic kidney disease-mineral bone disorder stimulates vascular calcification. Kidney Int 2014; 85:142-150.
8. Moe SM, Drü eke TB, Block GA, et al., Kidney Disease: Improving Global Outcomes (KDIGO) CKD-MBD Work Group. KDIGO clinical practice guideline for the diagnosis, evaluation, prevention, and treatment of chronic kidney disease-mineral and bone disorder (CKD-MBD). Kidney Int Suppl 2009; (113):S1-S130.
9. Block GA, Wheeler DC, Persky MS, et al. Effects of phosphate binders in moderate CKD. J Am Soc Nephrol 2012; 23:1407-1415.
10. Chue CD, Edwards NC, Moody WE, et al. Serum phosphate is associated with left ventricular mass in patients with chronic kidney disease: A cardiac magnetic resonance study. Heart 2012; 98:219-224.
11. Seifert ME, de Las Fuentes L, Rothstein M, et al. Effects of phosphate binder therapy on vascular stiffness in early-stage chronic kidney disease. Am J Nephrol 2013; 38:158-167.
12. Isakova T, Gutierrez OM, Smith K, et al. Pilot study of dietary phosphorus restriction and phosphorus binders to target fibroblast growth factor 23 in patients with chronic kidney disease. Nephrol Dial Transplant 2011; 26:584-591.
13. Oliveira RB, Cancela AL, Graciolli FG, et al. Early control of PTH and FGF23 in normophosphatemic CKD patients: A new target in CKD-MBD therapy? Clin J Am Soc Nephrol 2010; 5:286-291.
14. Danisi G, Caverzasio J, Trechsel U, et al. Phosphate transport adaptation in rat jejunum and plasma level of 1, 25-dihydroxyvitamin D3. Scand J Gastroenterol 1990; 25:210-215.
15. Cross HS, Debiec H, Peterlik M. Mechanism and regulation of intestinal phosphate absorption. Miner Electrolyte Metab 1990; 16 (2-3):115-124.
16. Sabbagh Y, O'Brien SP, Song W, et al. Intestinal npt2b plays a major role in phosphate absorption and homeostasis. J Am Soc Nephrol 2009; 20:2348-2358.
17. Katai K, Tanaka H, Tatsumi S, et al. Nicotinamide inhibits sodium-dependent phosphate cotransport activity in rat small intestine. Nephrol Dial Transplant 1999; 14:1195-1201.
18. Debiec H, Lorenc R. Identification of Na\+, Pi-binding protein in kidney and intestinal brush-border membranes. Biochem J 1988; 255:185-191.
19. Schiavi SC, Tang W, Bracken C, et al. Npt2b deletion attenuates hyperphosphatemia associated with CKD. J Am Soc Nephrol 2012; 23:1691-1700.
20. Radanovic T, Wagner CA, Murer H, Biber J. Regulation of intestinal phosphate transport. I. Segmental expression and adaptation to low-P(i) diet of the type IIb Na(\+)-P(i) cotransporter in mouse small intestine. Am J Physiol Gastrointest Liver Physiol 2005; 288:G496-500.
21. Isakova T, Ix JH, Sprague SM, et al. Rationale and approaches to phosphate and fibroblast growth factor 23 reduction in CKD. J Am Soc Nephrol 2015; 26:2328-2339.
22. Kuboyama N, Watanabe Y, Yamaguchi M, et al. Effects of niceritrol on faecal and urinary phosphate excretion in normal rats. Nephrol Dial Transplant 1999; 14:610-614.
23. Eto N, Miyata Y, Ohno H, Yamashita T. Nicotinamide prevents the development of hyperphosphataemia by suppressing intestinal sodium-dependent phosphate transporter in rats with adenine-induced renal failure. Nephrol Dial Transplant 2005; 20:1378-1384.
24. Blaine J, Chonchol M, Levi M. Renal control of calcium, phosphate, and magnesium homeostasis. Clin J Am Soc Nephrol 2015; 10:1257-1272.
25. Wu KI, Bacon RA, Al-Mahrouq HA, Kempson SA. Nicotinamide as a rapidacting inhibitor of renal brush-border phosphate transport. Am J Physiol 1988; 255 (1 Pt 2):F15-F21.
26. Kempson SA, Colon-Otero G, Ou SY, et al. Possible role of nicotinamide adenine dinucleotide as an intracellular regulator of renal transport of phosphate in the rat. J Clin Invest 1981; 67:1347-1360.
27. Berndt TJ, Pfeifer JD, Knox FG, et al. Nicotinamide restores phosphaturic effect of PTH and calcitonin in phosphate deprivation. Am J Physiol 1982; 242:F447-F452.
28. Shimoda K, Akiba T, Matsushima T, et al. [Niceritrol decreases serum phosphate levels in chronic hemodialysis patients]. Nihon Jinzo Gakkai Shi 1998; 40:1-7.
29. Mattiussi AJ, Blais D. Niacin versus niacinamide. CMAJ 1992; 147:990-991.
30. Knip M, Douek IF, Moore WP, et al. Safety of high-dose nicotinamide: A review. Diabetologia 2000; 43:1337-1345.
31. Dalton C, VanTrabert TC, Dwyer JX. Relationship of nicotinamide and nicotinic acid to hypolipidemia. Biochem Pharmacol 1970; 19:2609-2619.
32. Reiche I, Westphal S, Martens-Lobenhoffer J, et al. Pharmacokinetics and dose recommendations of Niaspan(R) in chronic kidney disease and dialysis patients. Nephrol Dial Transplant 2010; 26:276-282.
33. Takahashi Y, Tanaka A, Nakamura T, et al. Nicotinamide suppresses hyperphosphatemia in hemodialysis patients. Kidney Int 2004; 65:1099-1104.
34. Cheng SC, Young DO, Huang Y, et al. A randomized, double-blind, placebocontrolled trial of niacinamide for reduction of phosphorus in hemodialysis patients. Clin J Am Soc Nephrol 2008; 3:1131-1138.
35. Young DO, Cheng SC, Delmez JA, Coyne DW. The effect of oral niacinamide on plasma phosphorus levels in peritoneal dialysis patients. Perit Dial Int 2009; 29:562-567.
36. El Borolossy R, El Wakeel LM, El Hakim I, Sabri N. Efficacy and safety of nicotinamide in the management of hyperphosphatemia in pediatric patients on regular hemodialysis. Pediatr Nephrol 2016; 31:289-296.
37. Vasantha J, Soundararajan P, Vanitharani N, et al. Safety and efficacy of nicotinamide in the management of hyperphosphatemia in patients on hemodialysis. Indian J Nephrol 2011; 21:245-249.
38. Shahbazian H, Zafar Mohtashami A, Ghorbani A, et al. Oral nicotinamide reduces serum phosphorus, increases HDL, and induces thrombocytopenia in hemodialysis patients: A double-blind randomized clinical trial. Nefrologia 2011; 31:58-65.
39. Ix JH, Ganjoo P, Tipping D, et al. Sustained hypophosphatemic effect of oncedaily niacin/laropiprant in dyslipidemic CKD stage 3 patients. Am J Kidney Dis 2011; 57:963-965.
40. Rao M, SteffesM, Bostom A, Ix JH. Effect of niacin on FGF23 concentration in chronic kidney disease. Am J Nephrol 2014; 39:484-490.
41. Gale EA, Bingley PJ, Emmett CL, Collier T. European Nicotinamide Diabetes Intervention Trial (ENDIT): A randomised controlled trial of intervention before the onset of type 1 diabetes. Lancet 2004; 363:925-931.
42. Winter SL, Boyer JL. Hepatic toxicity from large doses of vitamin B3 (nicotinamide). N Engl J Med 1973; 289:1180-1182.
43. Chen AC, Martin AJ, Choy B, et al. A phase 3 randomized trial of nicotinamide for skin-cancer chemoprevention. N Engl J Med 2015; 373:1618-1626.
44. O'Brien T, Silverberg JD, Nguyen TT. Nicotinic acid-induced toxicity associated with cytopenia and decreased levels of thyroxine-binding globulin. Mayo Clin Proc 1992; 67:465-468.
45. Rottembourg JB, Launay-Vacher V, Massard J. Thrombocytopenia induced by nicotinamide in hemodialysis patients. Kidney Int 2005; 68:2911-2912.